Tarsus Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
TARS Tarsus Pharmaceuticals Inc
PTICW PropTech Investment II Equity Warrant Exp 8th Dec 2027 *W EXP 12/08/2027
TKPHF Takeda Pharmaceutical Co Ltd
O Realty Income Corp
HSTA Hestia Insight Inc
NRG NRG Energy Inc
MACK Merrimack Pharmaceuticals Inc
BMY Bristol-Myers Squibb Co
NDAQ Nasdaq Inc
UL Unilever PLC
Go

Health Care : Pharmaceuticals |
Company profile

Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic candidates to address ophthalmic conditions. Its lead product candidate, TP-03, is a therapeutic being developed for the treatment of blepharitis caused by the infestation of Demodex mites (Demodex blepharitis). TP-03 is a therapeutic based on the drug, lotilaner, which is designed to paralyze and eradicate mites and other parasites through the inhibition of parasite-specific gamma-aminobutyric acid-gated chloride (GABA-Cl) channels. The Company is also developing additional clinical-stage product candidates with lotilaner. These include TP-04 for the treatment of rosacea as well as TP-05 for Lyme prophylaxis and community malaria reduction.

Closing Price
$19.83
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)
Volume:
0

10-day average volume:
17,271
0

Display:

Providers:

UpdateCancel
4 providers
November 23, 2021
Tarsus Pharmaceuticals started at outperform with $55 stock price target at Oppenheimer

(END) Dow Jones Newswires November 23, 2021 08:26 ET (13:26 GMT) (MarketWatch)

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.